Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 200

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 200
---
 δand PI3K α/ δmedicines have been approved or in advanced development. Lenalidomide was approved for 2L FL. CD20 mAb includes 1) rituximab and rituximab+hyaluronidase approved for 1L CD20+, maintenance post 1L and 2L r/r CD20+ settings and 2) obinutuzumab approved in 1L and 2L r/r settings. CD20/CD3 BsAb includes 1) mosunetuzumab approved for≥3L FL, 2) epcoritamab approved for≥3L FL and 3) odronextamab under review for≥3L. CD19 CAR-T includes 1) axicabtagene was approved for≥3L FL, 2) tisagenlecleucel approved for≥3L FL and 3) lisocabtagene approved for≥3L FL. BTK zanubrutinib was approved for≥3L r/r FL. PI3K α/ δcopanlisib was approved for≥3L r/r FL, but subsequently withdrawn. PI3K δparsaclisib was filed for≥3L FL, but subsequently withdrawn.

For FL, in China, CD20 mAb MIL62 is in Phase III 2L r/r FL; CD20/CD47 BsAb amulirafusp alfa has readout Phase I/II data in≥2L settings. BTK zanubrutinib was approved for≥3L r/r FL. PI3K α/ δincludes 1) linperlisib approved for≥3L r/r FL, 2) copanlisib approved for≥3L r/r FL and 3) gilmelisib filed for≥3L r/r FL, but subsequently withdrawn. PI3K δparsaclisib was filed for≥3L r/r FL, but subsequently withdrawn.

Table of Contents

For epithelioid sarcoma specifically, other than tazemetostat, there are no therapies which have been approved. Epithelioid sarcoma, an INI1-negative tumor, is typically treated with surgical resection when it presents as localized disease. When epithelioid sarcoma recurs or metastasizes, it may be treated with systemic chemotherapy